In addition, interleukin-6 (IL-6) was suggested as a biomarker for more severe courses of COVID-19 [14], and tocilizumab, a humanized monoclonal antibody targeting the IL-6 receptor, has been evaluated as a potential therapeutic option for COVID-19 patients and was shown to improve outcomes, e.g., in critically ill patients with COVID-19 receiving organ support in ICUs [15,16]. This evidence concerns the gene IL6 and COVID-19.